BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, April 21, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

June 30, 2015

View Archived Issues

Volanesorsen named U.S. orphan drug for familial chylomicronemia syndrome

Read More

FluBlok Quadrivalent more effective than traditional influenza vaccine

Read More

Conatus reports baseline data from first patients in phase IIb trial of emricasan

Read More

Immunovaccine and Incyte collaborate to investigate combination of DPX-Survivac and epacadostat

Read More

Invenra and Oxford BioTherapeutics collaborate to discover therapeutic antibodies targeting cancer

Read More

Phase Ib results for BioChaperone Lispro in type 1 diabetes

Read More

SB-204 8% is well-tolerated in subjects with acne vulgaris

Read More

Model of cetuximab resistance in CRC allows testing of other treatments

Read More

Patrys awards Chinese license for cancer therapy PAT-SC1

Read More

Oral suspension formulation of Orfadin receives European approval

Read More

Bioiberica to start trials for PRJ-212 for Alzheimer's disease

Read More

European orphan drug designation for Cabaletta in spinocerebellar ataxia

Read More

Galectin Therapeutics initiates phase II study of GR-MD-02 in NASH

Read More

Sarepta Therapeutics completes NDA submission to FDA for eteplirsen

Read More

RedHill initiates phase I/II study of ABC-294640 in refractory DLBCL

Read More

rF-GM-CSF and rF-TRICOM are safe is patients with bladder carcinoma

Read More

Bristol-Myers Squibb develops HCV NS5A inhibitors

Read More

Glenmark Pharmaceuticals patents RORgamma-t modulators

Read More

Daiichi Sankyo discloses LCAT activators

Read More

Merck & Co. reports sGC activators

Read More

Shanghai Hansoh Biomedical presents ALK inhibitors

Read More

Incyte presents data on INCB-040093

Read More

FDA accepts IND for phase I trial of JCAR-017 for relapsed/refractory B-cell NHL

Read More

SrtarD6 gene polymorphism in Alzheimer's disease

Read More

Intercept files for approval of obeticholic acid for primary biliary cirrhosis in U.S. and E.U.

Read More

Bayer files for Japanese approval of BAY-81-8973 for hemophilia A

Read More

Novartis to acquire Spinifex Pharmaceuticals

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 20, 2026.
  • Man holding raised arm with illustrated overlay of nerves

    Biohaven reports details on discovery of BHV-2100

    BioWorld Science
    Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
  • Elderly woman holding illustration of brain with missing puzzle piece

    Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

    BioWorld
    The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
  • New GABA(B) receptor PAMs revealed in Addex Pharma patents

    BioWorld Science
    Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
  • Novel caspase-2 inhibitor shows in vivo neuroprotective effects

    BioWorld Science
    Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing